{"filing":{"accession_number":"0001193125-26-341298","cik":"0001953530","ticker":"OCSAW","company_name":"Oculis Holding AG","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"project_axis_6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1953530/000119312526341298/project_axis_6-k.htm"},"events":[{"id":26383,"run_id":23974,"accession_number":"0001193125-26-341298","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Oculis has entered into an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics for $3.8 million in cash plus up to 2.05 million ordinary shares. This is a material acquisition of a lead clinical-stage asset (currently in registrational trials with Breakthrough Therapy and PRIME designations) that terminates an existing license agreement and significantly reduces future royalty obligations, directly affecting the company's economic interest in a core pipeline asset.","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27480,"accession_number":"0001193125-26-341298","item_number":"EX-99.1","item_title":"ocs-ex99_1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Oculis has entered into an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics for $3.8 million in cash plus up to 2.05 million ordinary shares. This is a material acquisition of a lead clinical-stage asset (currently in registrational trials with Breakthrough Therapy and PRIME designations) that terminates an existing license agreement and significantly reduces future royalty obligations, directly affecting the company's economic interest in a core pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:00:40.232315+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27480,"accession_number":"0001193125-26-341298","item_number":"EX-99.1","item_title":"ocs-ex99_1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Oculis has entered into an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics for $3.8 million in cash plus up to 2.05 million ordinary shares. This is a material acquisition of a lead clinical-stage asset (currently in registrational trials with Breakthrough Therapy and PRIME designations) that terminates an existing license agreement and significantly reduces future royalty obligations, directly affecting the company's economic interest in a core pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:00:40.232315+00:00","company_name":"Oculis Holding AG","ticker":"OCSAW","filing_date":"2026-08-10"}]}